New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
Abstract CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) represents a significant advancement for patients with relapsed/refractory large B‐cell lymphoma (LBCL). Long‐term follow‐up confirms durable remissions in nearly half of the patients, a population that was previously estimated...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | eJHaem |
Subjects: | |
Online Access: | https://doi.org/10.1002/jha2.323 |